Kinesin
Signaling Pathway Map
Research Area
- Inhibitory Selectivity
- Solubility
| Catalog No. | Product Name | Solubility(25°C) | ||
|---|---|---|---|---|
| Water | DMSO | Alcohol | ||
| S1452 | Ispinesib (SB-715992) | <1 mg/mL | 103 mg/mL | 103 mg/mL |
| S2182 | SB743921 HCl | 22 mg/mL | 111 mg/mL | 111 mg/mL |
| S2731 | AZ 3146 | <1 mg/mL | 28 mg/mL | 91 mg/mL |
| S7090 | GSK923295 | <1 mg/mL | 100 mg/mL | 100 mg/mL |
| S7355 | ARQ 621 | <1 mg/mL | 100 mg/mL | 100 mg/mL |
| S5522 | H-Cys(Trt)-OH | -1 mg/mL | 5 mg/mL | -1 mg/mL |
| S8439 | Monastrol | <1 mg/mL | 58 mg/mL | 58 mg/mL |
| S8215 | BAY 1217389 | <1 mg/mL | 100 mg/mL | 3 mg/mL |
| S7488 | MPI-0479605 | <1 mg/mL | 62 mg/mL | 2 mg/mL |
- Kinesin Inhibitors (9)
- New Kinesin Products
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S1452 |
Ispinesib (SB-715992)Ispinesib (SB-715992) is a potent, specific and reversible inhibitor of kinesin spindle protein (KSP) with Ki app of 1.7 nM in a cell-free assay, no inhibition to CENP-E, RabK6, MCAK, MKLP1, KHC or Kif1A. Phase 2. |
Representative photographs of fluorescent staining of microtubules and nuclei in MDA-MB-231 cells 24 h post-treatment with 4 nM of ispinesib or vinblastine or their combination. Arrows and arrowheads denote mitotic cells with monoploar and bipolar spindles, respectively. Scale bars, 20 um.
|
|
| S2182 |
SB743921 HClSB743921 is a kinesin spindle protein (KSP) inhibitor with Ki of 0.1 nM, almost no affinity to MKLP1, Kin2, Kif1A, Kif15, KHC, Kif4 and CENP-E. Phase 1/2. |
HeLa cells expressing iRFP were seeded onto 96-well plates and incubated with buffer or different concentrations of SB743921.During the next five days, the plate was scanned with an infrared imaging system (upper panel) to quantify the infrared signals (lower panel). |
|
| S2731 |
AZ 3146AZ3146 is a selective Mps1 inhibitor with IC50 of ~35 nM, contributes to recruitment of CENP-E (kinesin-related motor protein), less potent to FAK, JNK1, JNK2, and Kit. |
Dose response curves for the treatment of breast cancer cell lines in the absence or presence of escalating doses of the TTK inhibitor (TTKi) AZ3146. The survival of cells was measured using the CellTitre MTS/MTA assay carried out 6 days after treatment. Percentage survival (n ¼ 3 per dose) was calculated as the percentage of the signal from treated cells to that from control cells. |
|
| S7090 |
GSK923295GSK923295 is a first-in-class, specific allosteric inhibitor of CENP-E kinesin motor ATPase with Ki of 3.2 nM, and less potent to mutant I182 and T183. Phase 1. |
(f) HeLa cells were treated with mitotic kinesin CENP-E inhibitor GSK923295 (50 nM) for 1 h to generate misaligned kinetochores. After fixation, cells were stained for ACA, tubulin, and TIP60. Statistical significance was tested by two-sided t-test and represented by asterisks corresponding to ***, p < 0.001. Scale bars, 5 μm. |
|
| S7355 |
ARQ 621ARQ 621 is an allosteric, and selective Eg5 mitotic motor protein inhibitor. Phase 1. |
||
| S5522New |
H-Cys(Trt)-OHH-Cys(Trt)-OH is a specific inhibitor of Eg5 that inhibits Eg5-driven microtubule sliding velocity in a reversible fashion with an IC50 of 500 nM. |
||
| S8439 |
MonastrolMonastrol is a cell-permeable small molecule inhibitor of kinesin-5(KIF11) which is essential for maintaining separation of the half-spindles. |
||
| S8215 |
BAY 1217389BAY 1217389 is an orally bioavailable, selective inhibitor of the serine/threonine kinase monopolar spindle 1 (Mps1) with IC50 values below 10 nmol/L while showing an excellent selectivity profile. |
||
| S7488 |
MPI-0479605MPI-0479605 is an ATP competitive and selective inhibitor of mitotic kinase Mps1 with IC50 of 1.8 nM, >40-fold selectivity over other kinases. |
